This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Childhood B Acute Lymphoblastic Leukemia, Childhood Burkitt Leukemia, Childhood Diffuse Large Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Stage III Childhood Large Cell Lymphoma or Stage IV Childhood Large Cell Lymphoma
and you are
between 6 and 17
years old
2
3
This is an advanced phase trial assessing
the effectiveness of the new treatment before being released on the market.
Show me locations

The purpose

This randomized phase II/III trial studies how well combination chemotherapy with or without rituximab works in treating younger patients with stage III-IV non-Hodgkin lymphoma or B-cell acute leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibody, such as rituximab, may block cancer growth in different ways by targeting certain cells. It is not yet known whether combination chemotherapy together with rituximab is more effective in treating patients with non-Hodgkin lymphoma or B-cell acute leukemia.

Provided treatments

  • Biological: Rituximab
  • Drug: Prednisone
  • Drug: Etoposide
  • Drug: Doxorubicin Hydrochloride
  • Drug: Cytarabine
  • Drug: Vincristine Sulfate
  • Drug: Cyclophosphamide
  • Drug: Methotrexate
  • Drug: Methylprednisolone
  • Drug: Leucovorin Calcium
  • Drug: Therapeutic Hydrocortisone
  • Other: Laboratory Biomarker Analysis

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01595048. The sponsor of the trial is Children's Oncology Group and it is looking for 640 volunteers for the current phase.
Official trial title:
Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients